NUVB
Nuvation Bio Inc
NYSE: NUVB · HEALTHCARE · BIOTECHNOLOGY
$4.34
-4.82% today
Updated 2026-04-29
Market cap
$1.51B
P/E ratio
—
P/S ratio
23.99x
EPS (TTM)
$-0.60
Dividend yield
—
52W range
$2 – $10
Volume
4.2M
Nuvation Bio Inc (NUVB) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $7.87M | $62.90M |
| Revenue growth (YoY) | — | — | — | — | — | — | — | +699.0% |
| Cost of revenue | — | — | $103000.00 | $368000.00 | $484000.00 | $222000.00 | $7.08M | $8.44M |
| Gross profit | — | — | $-103000.00 | $-368000.00 | $-484000.00 | $-222000.00 | $795000.00 | $54.46M |
| Gross margin | — | — | — | — | — | — | 10.1% | 86.6% |
| R&D | $482667.00 | $25.11M | $32.60M | $69.04M | $87.81M | $71.29M | $524.19M | $115.11M |
| SG&A | $509333.00 | $6.59M | $10.95M | $24.28M | $31.92M | $28.53M | $66.73M | $151.56M |
| Operating income | $-992000.00 | $-32.10M | $-43.55M | $-93.32M | $-119.73M | $-99.82M | $-592.63M | $-213.06M |
| Operating margin | — | — | — | — | — | — | -7527.3% | -338.7% |
| EBITDA | — | $-32.09M | $-41.56M | $-93.13M | $-119.53M | $-75.58M | $-566.91M | $-190.94M |
| EBITDA margin | — | — | — | — | — | — | -7200.7% | -303.6% |
| EBIT | $-992000.00 | $-32.10M | $-41.66M | $-93.32M | $-119.73M | $-75.80M | $-567.60M | — |
| Interest expense | $0.00 | $0.00 | $0.00 | $644000.00 | $9.16M | $0.00 | $341000.00 | $13.68M |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-992000.00 | $-33.55M | $-41.66M | $-86.85M | $-104.20M | $-75.80M | $-567.94M | $-204.63M |
| Net income growth (YoY) | — | -3282.3% | -24.2% | -108.5% | -20.0% | +27.3% | -649.2% | +64.0% |
| Profit margin | — | — | — | — | — | — | -7213.8% | -325.3% |